Focus: R-Pharm US is a specialty biotech focused on acquiring and commercializing small-molecule products across cardiovascular, neurology, infectious disease, oncology, and respiratory indications, headquartered in Princeton, NJ since 2014.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
2 recent layoff filings (12 mo) — 150 affected
Source: state DOL filings via Big Local News
No open roles listed right now. Follow R-Pharm US to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for R-Pharm US
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from R-Pharm US's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Represents 33% of company revenue but faces patent expiration in <2 years, creating critical commercial risk and potential for margin compression.
Second-largest revenue driver; established as generic/biosimilar product providing consistent cash flow in mature market.
Cardiovascular franchise product facing patent cliff in 2028; part of broader ARB portfolio under competitive pressure.
Neuropathic pain/RLS specialist product in peak revenue phase with patent protection extending to 2029.
Gastroenterology product with longest patent runway (through 2037) providing long-term revenue stability.
Diabetes care product with extended patent protection through 2039; addresses critical acute care market in endocrinology.
615 discontinued, 173 duplicate formulations not shown
+18 more products with revenue data
No open positions listed yet. Check their careers page directly.
Source: USCIS H-1B Employer Data Hub
+115 more products
Source: state DOL filings, aggregated via Big Local News
No FDA compliance warnings or WARN Act filings on record; however, zero hiring and imminent patent cliffs create structural instability risk.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo